Sympatho-Excitation in Pulmonary Hypertension: The Potential Role of Pulmonary Arterial Baroreceptors: An Acute Physiologic Intervention Study
Related Experiment Video
Updated: Feb 4, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Michael J Plunkett1,2, Ana L C Sayegh1, Robert A Lewis3
1Manaaki Manawa-The Centre for Heart Research, Department of Physiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Background And Objective:
Sympathetic nerve activity is heightened in pulmonary arterial hypertension (PAH), promotes deleterious pulmonary vascular and right ventricular remodelling, and is associated with worsened exercise capacity and mortality. Pulmonary arterial baroreceptors, activated by increased pulmonary arterial pressure and distension, could drive muscle sympathetic nerve activity (MSNA) in pulmonary hypertension (PH). We hypothesised that pulmonary arterial baroreceptor unloading using nebulised iloprost as a pulmonary arterial vasodilator would lower MSNA in clinically stable treated PAH and chronic thromboembolic PH (CTEPH) patients.
Methods:
In eleven PH patients (9 PAH, 2 CTEPH; 6 female; age 54 ± 14 years) common peroneal nerve microneurography was performed to record MSNA (n = 9) at baseline (10 min) and immediately following iloprost nebulisation (10 min). Concurrent measures of cardiorespiratory physiology and pulmonary haemodynamics (transthoracic echocardiography) were obtained.
Results:
Iloprost reduced systolic pulmonary artery pressure (50 ± 19 mmHg baseline vs. 44 ± 15 mmHg iloprost; p = 0.040), and increased right ventricular outflow tract acceleration time (RVOT AT; 99 ± 15 ms baseline vs. 117 ± 16 ms iloprost; p < 0.001). Although no overall change was seen in MSNA (p > 0.05), the magnitude of change in MSNA burst size was inversely associated with the increase in RVOT AT (R2 = 0.667, p = 0.0133).
Conclusion:
These findings provide evidence suggestive of possible pulmonary arterial baroreceptor influence of MSNA burst amplitude in some PH patients. Pulmonary arterial baroreceptor activation may be a contributory mechanism to adverse sympatho-excitation in PH.
Clinical Trial Registration:
ACTRN12622000494730.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

